SCHEMBL11069331

SCHEMBL11069331

CCCCCCCCCC/C1=C/CCCCCC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
ALOX15 P16050 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.41
PKM P14618 1/20 0.41
CXCR3 P49682 1/20 0.39
RAB9A P51151 2/20 0.39
USP2 O75604 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NPC1 O15118 1/20 0.38
EPHX1 P07099 1/20 0.38
TNNC1 P63316 3/20 0.38
SGPL1 O95470 1/20 0.38
S1PR4 O95977 1/20 0.38
S1PR1 P21453 1/20 0.38
GPR183 P32249 1/20 0.38
CERS2 Q96G23 1/20 0.38
S1PR3 Q99500 1/20 0.38
S1PR5 Q9H228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17768658 1.00 ALDH1A1 (0.45) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3
SCHEMBL28297898 1.00 ALDH1A1 (0.45) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3
SCHEMBL29212867 1.00 ALDH1A1 (0.45) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3
SCHEMBL28336524 1.00 ALDH1A1 (0.45) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3
SCHEMBL11069335 1.00 ALDH1A1 (0.45) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3
SCHEMBL25337874 1.00 ALDH1A1 (0.45) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3
SCHEMBL17768660 1.00 ALDH1A1 (0.45) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3
SCHEMBL11236830 0.98 ALDH1A1 (0.46) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3
SCHEMBL61669 0.98 ALDH1A1 (0.46) ALDH1A1ALOX15SMN1; SMN2PKMRAB9A
SCHEMBL11236833 0.98 ALDH1A1 (0.46) ALDH1A1ALOX15SMN1; SMN2PKMCXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332112-A1 IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2025-10-30 US disclosed
EP-4574172-A2 IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2025-06-25 EP disclosed
EP-4466250-B1 IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2025-03-26 EP disclosed
EP-4466250-A1 IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2024-11-27 EP disclosed
WO-2023144798-A1 IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2023-08-03 WO disclosed
US-10005947-B2 Modified hydrocarbon resins as fluid loss additives INGEVITY SOUTH CAROLINA, LLC (US) 2018-06-26 US disclosed
EP-3071782-A1 MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES Georgia-Pacific Chemicals LLC (US) 2016-09-28 EP disclosed
WO-2015077215-A1 MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES GEORGIA-PACIFIC CHEMICALS LLC (US) 2015-05-28 WO disclosed
US-20150136402-A1 MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES GEORGIA-PACIFIC CHEMICALS LLC (US) 2015-05-21 US disclosed
US-4433100-A DICYCLOPENTADIENE, NON-AROMATIC UNSATURATED HYDROCARBON, FATTY OR ROSIN ACID NEVILLE CHEMICAL COMPANY (US) 1984-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332112-A1 IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES CETP, NPC1L1, ABCB4 ALDH1A1 3387/4885ALOX15 379/4885SMN1; SMN2 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.